Evofem Biosciences issues $1.42M convertible notes and warrants to Aditxt

Evofem Biosciences, Inc.

Aggregate principal amount $1,423,076.92; warrants to purchase 92,407,592 shares.
Aditxt paid ~$650 per $1,000 principal; net proceeds ~$925,000.
Notes bear 8% interest (12% upon default), mature June 26, 2028.
Conversion/exercise price $0.0154 per share; 9.99% beneficial ownership cap.
Warrants exercisable immediately, expire in 5 years, allow cashless exercise.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.